These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26248464)

  • 1. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
    Castañón E; Rolfo C; Viñal D; López I; Fusco JP; Santisteban M; Martin P; Zubiri L; Echeveste JI; Gil-Bazo I
    J Transl Med; 2015 Aug; 13():257. PubMed ID: 26248464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chen YC; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    Lung Cancer; 2016 Aug; 98():99-105. PubMed ID: 27393514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
    Gao G; Ren S; Li A; Xu J; Xu Q; Su C; Guo J; Deng Q; Zhou C
    Int J Cancer; 2012 Sep; 131(5):E822-9. PubMed ID: 22161771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
    Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
    Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
    Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
    Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
    Spaans JN; Goss GD
    Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.
    Chang YP; Chen YM; Lai CH; Lin CY; Fang WF; Huang CH; Li SH; Chen HC; Wang CC; Lin MC
    PLoS One; 2017; 12(6):e0178676. PubMed ID: 28591157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
    Okuma Y; Kashima J; Watanabe K; Homma S
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1601-1611. PubMed ID: 29858682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.
    Imai H; Shukuya T; Takahashi T; Fujiwara S; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Harada H; Endo M; Nakajima T; Yamamoto N
    Anticancer Res; 2013 Aug; 33(8):3279-84. PubMed ID: 23898092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.